Physician profile
Richard E Hanson
NPI 1568412963
$3,415.55
in general payments reported to CMS, 2019-2025
32 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,386 · 2022: $1,419 · 2023: $174 · 2024: $287 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $682.02 | 2021-2022 | |
| Daiichi Sankyo INC. | $502.51 | 2021-2025 | Enhertu |
| Incyte Corporation | $210.08 | 2021-2024 | Jakafi, Monjuvi |
| Janssen Biotech, INC. | $187.21 | 2022-2024 | Carvykti |
| Novartis Pharmaceuticals Corporation | $179.68 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $156.92 | 2022-2025 | Imfinzi, Enhertu, Tagrisso |
| Karyopharm Therapeutics INC. | $144.39 | 2021-2024 | Xpovio |
| Seagen INC. | $136.83 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $121.36 | 2022-2025 | Keytruda |
| Glaxosmithkline, LLC. | $117.21 | 2022-2024 | Ojjaara |
| Astellas Pharma US INC | $96.85 | 2021-2025 | Vyloy |
| E.R. Squibb & Sons, L.L.C. | $92.21 | 2022-2023 | Opdivo |
| Epizyme, INC. | $88.93 | 2021 | |
| Amgen INC. | $85.27 | 2021-2022 | |
| Celgene Corporation | $78.87 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $72.14 | 2021-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $67.08 | 2021-2023 | Imbruvica |
| Lilly USA, LLC | $53.25 | 2021-2023 | Verzenio |
| Genzyme Corporation | $51.15 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.93 | 2024-2025 | Ninlaro, Iclusig |
| Tersera Therapeutics LLC | $39.26 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $31.32 | 2022 | |
| Puma Biotechnology, INC. | $22.69 | 2024 | |
| Genmab U.S., INC. | $22.23 | 2023 | Epkinly |
| Kite Pharma, INC. | $21.18 | 2022 | |
| Kyowa Kirin, INC. | $17.73 | 2022 | |
| Springworks Therapeutics, INC. | $17.38 | 2025 | Ogsiveo |
| G1 Therapeutics, INC. | $16.71 | 2022 | |
| Gilead Sciences, INC. | $16.63 | 2022 | |
| Deciphera Pharmaceuticals INC. | $14.63 | 2021 | |
| Clovis Oncology, INC. | $14.46 | 2022 | |
| Stemline Therapeutics INC. | $13.44 | 2023 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.